Member Info for rivaldo

and up above 5% with 15.2m shares: Http://www.investegate.co.uk/severfield-plc--sfr-/rns/holding-s--in-company/201611240852160480Q/

GMAA has become one of Unicorn AIM VCT's largest ten investments, and in their results this morning they have this interesting paragraph: Http://www.investegate.co.uk/unicorn-aim-vct-plc--uav-/rns/annual-financial-report/201611240700089970P/ "Gama Aviation (-55%) is one of the world's largest business aviation service providers. Despite continued strong growth in revenues, the business continues to record losses after currency adjustments. The weakening of Sterling combined with a material investment in international expansion, has resulted in Gama's market capitalisation remaining under significant pressure, with the share price declining by over 50% in the period under review. The fundamental strength of the Gama business model is that revenues are underpinned by long term renewable contracts, which, when combined with geographical diversity and proven industry expertise, should enable the business to deliver improving financial results, despite challenging trading conditions in the UK and Europe."

Liontrust are still buying - above 11% now with 20,14m shares: Http://www.investegate.co.uk/ideagen-plc/rns/holding-s--in-company/201611240700109727P/

Today's Autumn Statement noted "that the government will spend £450m of the NPIF cash on trials for digital signalling technologies on the rail networks, with an aim of expanding capacity and improving reliability": Http://www.publictechnology.net/articles/news/autumn-statement-commits-millions-full-fibre-5g-and-digital-railway-signalling It just so happens that the Giffen Group - acquired by RNWH just 3 weeks ago - specialises in "the capability to design, install, test and commission major signalling projects": Https://giffengroup.co.uk/sector/signalling/ Bingo :o))

The IC are definitive - Buy: Http://www.investorschronicle.co.uk/2016/11/22/shares/news-and-analysis/severfield-s-ambitions-look-well-grounded-HtZsVRaULOTdLKxiSMBqIO/article.html Extract: "The group's order book stood at £315m at the beginning of November, representing a six-year high, and a 17 per cent increase in just five months. Major contract wins in the first half include a tower project at 22 Bishopsgate, London and the Graphene Innovation Centre in Manchester. The backlog is expected to feed through into increased production volumes and revenues in the second half. Jefferies has upgraded its forecasts for March 2017 full-year profits and EPS to £17.9m and 5p, respectively, rising to £20.8m and 5.7p in 2018 (from £13.2m and 3.7p in 2016)." "IC VIEW: The group is set fair to achieve its target of doubling its underlying profit before tax over the next four years. Strip out net cash, equivalent to 8.2p a share, and Severfield trades at just 11 times FY2018 earnings - get your wallet out. Buy."

A further 25,000 shares bought at 20p late yesterday a full 1p above the 19p published offer price! Nice....

Standard Life are above 12% now having bought over £1m more of stock: Http://www.investegate.co.uk/accesso-technology--acso-/rns/holding-s--in-company/201611221754448825P/

Http://www.fool.co.uk/investing/2016/11/22/renew-holdings-plc-looks-set-for-further-growth-after-10-rise-in-earnings/ Conclusion: "Renew has shown good PEG valuations in recent years, and though forecasts suggest a bit of a rise to 0.7 in the coming year, I think that's still within an attractive growth range. With a forward P/E of 12.3, I can see a small cap growth opportunity here, and with a market cap of £240m company, I don't think the risks are too great."

Brief analyst comment FYI: Http://www.building.co.uk/news/severfield-eyes-market-beating-figures-after-interims-tonic/5085041.article Extract: "Chief executive Ian Lawson (pictured), who was brought in to turn around the loss-making business by chairman John Dodds in November 2013 after leaving Kier earlier that year, said he expected profit for the full year to be ahead of expectations. Cenkos analyst Kevin Cammack said: "These are cracking interims featuring stand-out margin growth from 4.3% to 7%." He added that he expected full year profits to be around £18m, up from his previous estimate of £16.5m. Lawson added: "We have a strong platform from which to implement our strategy, which targets to double our underlying profit before tax over the next four years and continue to create value for our shareholders." The firm increased its dividend by 40% to 0.7 pence."

Regent Pacific has zoomed upwards, and was up another 20% overnight to 0.61, so PEBI's holding must be worth around £0.6m now - double the £0.3m at 30th June. For the record, here's the portfolio at 30th June (the m/cap is around £1.7m): Investments as at 30 June 2016 Value % of Total Portfolio Magna Biopharma Income Fund £1,312,807 56.4% Regent Pacific Group £302,568 12.9% Summit Corporation £197,513 8.5% Other quoted holdings £114,716 4.9% Other unquoted holdings £401,964 17.3% Total £2,329,568 100.0%

Worth also noting that this week's floods will likely give rise to lots of short notice additional work in terms of (a) alleviation and (b) rail repairs for Network Rail a la Dawlish - for example, there's a big operation going on in Exeter where the line will be closed for at least 2 days due to flood damage.

A bit of buying interest today. CHT issued a very positive trading update last year on 19th November (a Thursday) - hopefully a similar update will be issued at the end of this week, or at least before the end of December.

Numis have increased their price target to 450p (from 390p): Https://www.thecerbatgem.com/2016/11/22/numis-securities-ltd-boosts-renew-holdings-plc-rnwh-price-target-to-gbx-450.html

...and another nice move up today. Looks like our seller has been cleared out.

Encouraging comments here from the FD and MD (Andrew Shepherd). I wonder what the share price will be once the market latches on to the possibility of $115m of revenues from CD4 kits. Just a fraction of that would do wonders for a small cap like ODX.... Http://www.heraldscotland.com/business/14918533.Omega_ponders_allergen_division_disposal/ Extract: "Kieron Harbinson finance director: “It’s clearly early days; there needs to be an engagement programme with IDS. We will examine all options, but the fact they have made an approach tells us they recognise the value of the asset we’ve created over the past five years. Until there is clarification we will continue to develop the range of tests.” In October Omega CE-Marked its allergy launch panel, comprising 41 allergens which are capable of being run on IDS’ iSYS instrument. There are plans to grow this number to 120 – for which it received a £1.8m grant from Scottish Enterprise in August. The company has also made “significant progress” with its Visitect CD4 product. After lengthy delays, the tool for determining in the field whether HIV patients require retroviral drug treatment, has now been tested in more than 500 patients in three UK hospitals. Production will now commence on 10,000 devices for external field trials in India, France and sub-Saharan Africa. “A lot of data is going to come from these studies in the first calendar quarter,” said Mr Shepherd. “It takes some time to verify all that data so we’re expecting at the moment we’ll be launching the product with a CE-Marking in the second half of calendar 2017.” The World Health Organisation has estimated that around 22 to 23 million CD4 kits could be required per year, retailing at $5. “There is a significant market out there and everyone we speak to in this global health arena is saying we need this product, we need it desperately, right down at field level,” said Mr Shepherd. The company’s allergy and autoimmune division saw sales grow 11 per cent to £1.76m, while its infectious disease division grew sales by one per cent to £1.23m. In this area its Pune site in India is now producing Malaria point of care kits, which Mr Shepherd said would drive growth in that division. “We’ve invested £1m in Pune and it’s now time for that to start generating a commercial return,” said Mr Harbison. “Malaria will be first but we’ve got a pipeline of future products to come of that facility.” Its food intolerance division grew 15 per cent to £3.84m, driven by ongoing success in the US. Omega also noted growth in Middle East and India, where sales grew 46 per cent. "

A couple of days of rises - hopefully the tide has turned here. With almost a third of the m/cap backed up by well over £100m cash, the ex-cash P/E must be in single figures even on the lowest forecasts for this year from Shore Capital of 15.76p EPS (with a 13.95p dividend).

Moved up another 1p on just 10k of buys.....new recent high now. At 37p it's still on a single-figure P/E given 3.8p EPS forecasts for this year and 4p next year.

205p....not a bad start, but only 12% of irrevocables obtained to date. Let the bidding war commence :o))

H1 results are terrific, and most importantly full year results will be "comfortably ahead of expectations". Lots to go for given order books etc. SFR was always rated at a premium in the past - if it returns to those valuations then we could see 100p+ over the coming months: Http://www.investegate.co.uk/severfield-plc--sfr-/rns/half-year-report/201611220700097610P/ "I am delighted with our strong performance in the first half, which has continued since the period end. Margins are significantly up, our order book has continued to rise to a six year high whilst our pipeline remains steady. In combination with the strong cash generation in the first half, this has given us the confidence to increase the interim dividend by 40% and we expect profit growth for the full year to be comfortably ahead of expectations."

Results out and at the top end of expectations with 27.43p EPS and an 8p dividend, plus almost £5m net cash (spent post year-end on the new acquisition). Forecasts for this year are just over 32p EPS, which looks within reach given the increased order books, acquisition etc: Http://www.investegate.co.uk/renew-holdings-plc--rnwh-/rns/final-results/201611220700077508P/ An optimistic outlook, and order books nicely up, particularly Engineering Services. Looks like gas and telecoms continue to improve too.